[go: up one dir, main page]

ECSP088262A - ALBUMIN FUSION PROTEINS - Google Patents

ALBUMIN FUSION PROTEINS

Info

Publication number
ECSP088262A
ECSP088262A EC2008008262A ECSP088262A ECSP088262A EC SP088262 A ECSP088262 A EC SP088262A EC 2008008262 A EC2008008262 A EC 2008008262A EC SP088262 A ECSP088262 A EC SP088262A EC SP088262 A ECSP088262 A EC SP088262A
Authority
EC
Ecuador
Prior art keywords
albumin fusion
fusion proteins
vectors
host cells
methods
Prior art date
Application number
EC2008008262A
Other languages
Spanish (es)
Inventor
Craig Rosen
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of ECSP088262A publication Critical patent/ECSP088262A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención comprende proteínas de fusión de albúmina. Las moléculas de ácido nucleicoque codifican las proteínas de fusión de albúmina de la invención también están comprendidas en la invención, así como los vectores que contienen estos ácidos nucleicos, las células hospederas transformadas con estos vectores de ácidos nucleicos, y los métodos de hacer las proteínas de fusión de albúmina de la invención y de usar estos ácidos nucleicos, vectores, y/o células hospederas. Adicionalmente, la presente invención incluye composiciones farmacéuticas que comprenden las proteínas de fusión de albúmina y los métodos de tratamiento, prevención o mejoramiento de las enfermedades, trastornos o condiciones utilizando las proteínas de fusión de albúmina de la invención.The present invention comprises albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also included in the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors, and methods of making proteins. albumin fusion of the invention and using these nucleic acids, vectors, and / or host cells. Additionally, the present invention includes pharmaceutical compositions comprising albumin fusion proteins and methods of treatment, prevention or improvement of the diseases, disorders or conditions using the albumin fusion proteins of the invention.

EC2008008262A 2005-08-12 2008-03-12 ALBUMIN FUSION PROTEINS ECSP088262A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15

Publications (1)

Publication Number Publication Date
ECSP088262A true ECSP088262A (en) 2008-05-30

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008262A ECSP088262A (en) 2005-08-12 2008-03-12 ALBUMIN FUSION PROTEINS

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
CA2554089C (en) 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
BRPI0716744A2 (en) * 2006-09-14 2016-10-04 Human Genome Sciences Inc albumin fusion proteins
CN107011431B (en) 2007-01-30 2020-11-06 埃皮瓦克斯公司 Regulatory T cell epitopes, compositions and uses thereof
JP5685529B2 (en) 2008-06-13 2015-03-18 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダＰｒｏｙｅｃｔｏ Ｄｅ Ｂｉｏｍｅｄｉｃｉｎａ Ｃｉｍａ， Ｓ．Ｌ． Complexes for the administration of compounds having biological activity
JP2012515222A (en) 2009-01-16 2012-07-05 テバ ファーマシューティカル インダストリーズ リミテッド Stable preparation of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
ES2630253T3 (en) 2009-02-11 2017-08-18 Albumedix A/S Albumin variants and conjugates
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
US8748380B2 (en) * 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
EP2682128B1 (en) * 2011-02-28 2017-11-08 National Cerebral and Cardiovascular Center Atrial natriuretic peptide or brain natriuretic peptide for use in preventing metastasis
CN104011072B (en) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450019A1 (en) 2011-10-21 2014-01-10 Abbvie Inc Methods for treating HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US11370827B2 (en) 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
PT3564260T (en) 2012-02-15 2023-01-18 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
ES2664328T3 (en) 2012-03-16 2018-04-19 Albumedix A/S Albumin variants
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
CN110054699A (en) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 Factor IX compound with XTEN and vWF ELISA albumen, and application thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
BR112015010318A2 (en) 2012-11-08 2017-08-22 Albumedix As ALBUMIN VARIANTS
RS64664B1 (en) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Optimized factor viii gene
KR20150118123A (en) 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 Pharmacokinetic animal model
US10588949B2 (en) 2013-03-15 2020-03-17 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
CN105392495A (en) 2013-06-28 2016-03-09 比奥根Ma公司 Thrombin cleavable linkers with XTEN and uses thereof
TW202003554A (en) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 Factor VIII-XTEN fusions and uses thereof
HUE057005T2 (en) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Column virus inactivation procedures
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
DK3091997T5 (en) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc CHIMERIC FACTOR VIII PROTEINS AND USES THEREOF
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
EA201700181A1 (en) 2014-10-14 2017-09-29 Галозим, Инк. COMPOSITIONS OF ADENOSINDEMINASE-2 (ADA-2), THEIR OPTIONS AND METHODS OF USE
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
BR112018002150A2 (en) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc factor ix fusion proteins and methods of manufacturing and using them
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
ES2863278T3 (en) 2015-10-02 2021-10-11 Silver Creek Pharmaceuticals Inc Bispecific therapeutic proteins for tissue repair
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
HRP20221089T1 (en) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimized factor viii genes
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
WO2018082758A1 (en) 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
IL308416B2 (en) 2016-12-02 2025-08-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
CR20190389A (en) 2017-01-31 2019-11-26 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
WO2018193033A1 (en) * 2017-04-20 2018-10-25 Novo Nordisk A/S Methods of purification of albumin fusion proteins
TWI904068B (en) 2017-08-09 2025-11-11 美商生物化學醫療公司 Nucleic acid molecules and uses thereof
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
BR112020022164A2 (en) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. methods of treating hemophilia a
CA3104686A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf-21 formulations
CA3108799A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
AU2019393880A1 (en) 2018-12-06 2021-07-15 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor IX
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
EP4171657A1 (en) 2020-06-24 2023-05-03 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
WO2022030580A1 (en) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 Novel long-acting adrenomedullin derivative, method for producing same and pharmaceutical use thereof
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
US20250333481A1 (en) * 2022-10-11 2025-10-30 Jcr Pharmaceuticals Co., Ltd. Fusion protein of serum albumin and physiologically-active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277889B1 (en) * 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
EP1594530A4 (en) * 2003-01-22 2006-10-11 Human Genome Sciences Inc Albumin fusion proteins
CA2554089C (en) * 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
TNSN08064A1 (en) 2009-07-14
WO2007021494A3 (en) 2007-07-26
MA29836B1 (en) 2008-10-03
IL189246A0 (en) 2008-08-07
WO2007021494A2 (en) 2007-02-22
KR20080071119A (en) 2008-08-01
EP1924596A2 (en) 2008-05-28
MX2008001865A (en) 2008-04-15
AU2006280312A1 (en) 2007-02-22
JP2009504157A (en) 2009-02-05
CA2618476A1 (en) 2007-02-22
NO20081233L (en) 2008-05-09
BRPI0614761A2 (en) 2009-05-19
EP1924596A4 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
ECSP088262A (en) ALBUMIN FUSION PROTEINS
MX2009002816A (en) Albumin fusion proteins.
WO2007146038A3 (en) Albumin fusion proteins
BRPI0507026A (en) albumin fusion proteins
ES2353814T3 (en) RECOMBINANT N-GLYCOSILATED PROTEINS OF PROCEDURAL CELLS.
EA201690946A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
DOP2018000245A (en) GDF15 FUSION PROTEINS AND USES OF THESE
MX2020009514A (en) ANTI-CLAUDIN 18.2 ANTIBODIES (CLDN18.2).
HN2006016512A (en) ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
MA32771B1 (en) FGF21 MUTANTS AND USES THEREOF
BR112019005587A2 (en) recombinant binding proteins and their use
UY29344A1 (en) HUMANIZED ANTIAMILOID ANTIBODIES
EA201001204A1 (en) METHODS AND COMPOSITIONS IN WHICH APPLY KLOTHO-FGF POLYPEPTIDES FUSED
CY1114265T1 (en) ALBUMIN Fusion Protein
CR8978A (en) UNION DOMAIN FUSION PROTEINS
CY1110860T1 (en) REVERSE TRANSLATION OF Poultry Telomerase
BRPI0511118A (en) untranscribed haemophilus influenzae polypeptides
MX362981B (en) Artificial nucleic acid molecules for improved protein or peptide expression.
BR112017020986A2 (en) recombinant binding proteins and their use
MX2009004243A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use.
EA201391632A1 (en) AMINO ACID SEQUENCES ARE DIRECTED AGAINST IL-17A, IL-17F AND / OR IL-17A / F AND CONTAINING THEIR POLYPEPTIDES
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
WO2003030821A3 (en) Albumin fusion proteins
ECSP077240A (en) IMPROVED APROTININ VARIANTS
ATE533837T1 (en) MICROGININ-PRODUCING PROTEINS AND NUCLEIC ACIDS ENCODING A MICROGININ GENE CLUSTER AND METHODS FOR PRODUCING MICROGININS